Overview

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Metformin
Sitagliptin Phosphate